UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates
May 09, 2023 16:05 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
April 24, 2023 07:00 ET
|
Unity Biotechnology, Inc.
A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity (BCVA) of +6.2 ETDRS letters from baseline at 48 weeks ...
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
April 23, 2023 18:00 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., April 23, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
March 27, 2023 07:30 ET
|
Unity Biotechnology, Inc.
UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with...
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
March 15, 2023 16:05 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
February 28, 2023 16:05 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference
February 15, 2023 08:00 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study
February 09, 2023 08:00 ET
|
Unity Biotechnology, Inc.
-Investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., to be held on Tuesday, February 14, 2023 at 7:00 a.m. PT/ 10:00 a.m. ET- -Complete 16- and 24-week safety and efficacy data from...
UNITY Biotechnology Reports Granting of New Employment Inducement Award
January 18, 2023 08:00 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates
November 08, 2022 16:10 ET
|
Unity Biotechnology, Inc.
- Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in...